Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

NCT01200992 is registered in ClinicalTrials.gov with Bioniche Life Sciences Inc. as lead sponsor.

NCT NCT01200992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01200992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Lead sponsor
Bioniche Life Sciences Inc.
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2010
Completion date
December 31, 2013
Enrollment
84 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

bladder neoplasm, carcinoma in situ, mycobacterium, neoplasm recurrence, local, transitional cell, carcinoma